Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants

Vincent Geldhof1, Christophe Vandenbriele2, Peter Verhamme2 and Thomas Vanassche2,3*

Abstract

Increasing age and renal impairment are risk factors for venous thrombosis but also for anticoagulant-induced bleeding. In large-scale phase III trials, non-VKA oral anticoagulants (NOACs) were at least as effective and safe for the treatment of acute venous thromboembolism as warfarin. Here, we review the efficacy and safety of dabigatran, rivaroxaban, apixaban and edoxaban in the subgroups of elderly patients (≥75 years) and patients with impaired renal function (creatinine clearance ≤50 ml/min). In all phase III trials, the efficacy of NOACs in the prevention of recurrent VTE was conserved both in the elderly subgroup and in the subgroup with impaired renal function. In a meta-analysis of the pooled results, NOACs reduced VTE recurrence compared with warfarin in elderly patients. In elderly patients and patients with impaired renal function, the safety of NOACs was in line with the results of the overall study.

NOACs may offer an effective, safer and more convenient alternative for VKAs also in the elderly. However, the efficacy/safety profile of NOACs in the aged population needs to be confirmed in real-life.

Keywords: Venous thromboembolism, Elderly, Renal insufficiency, Novel oral anticoagulants, Non-VKA-acting oral anticoagulants

Introduction

Venous thromboembolism (VTE), with an annual incidence of 1.5-3.0 cases per 1000 individuals, is the third most common cause of cardiovascular disease and death after myocardial infarction and stroke [1-3]. VTE constitutes a spectrum ranging from asymptomatic distal deep venous thrombosis (DVT) and subsegmental pulmonary embolism (PE), to limb threatening DVT and fatal PE [2].

Age is an important risk factor for VTE and VTE recurrence. The risks for DVT and PE are 4 to 6 times higher in patients above 70 years old compared to younger patients [4,5], and this risk doubles with each decade of aging [6]. Importantly, elderly patients also exhibit a higher case-fatality rate due to more frequent fatal PE (odds ratio in patients aged >75 years 2.31 [7]) and coexistent comorbidities. The diagnosis of VTE in the elderly also poses particular challenges, as an atypical presentation and a reduced sensitivity and specificity of both clinical scoring systems and laboratory parameters may impede a timely diagnosis [8].

Age is not only a risk factor for VTE, but also increases the risk of bleeding related to anticoagulant treatment. The risk for major bleeding complications in anticoagulated patients is 2.5% per year in those aged over 80, compared to 0.9% per year in younger patients [8-11]. Until recently, Vitamin K Antagonists (VKAs) were the only available oral anticoagulants. Due to their unpredictable pharmacokinetic profile, the management of VKAs was particularly problematic in the elderly, where comorbidities and concomitant medication may further increase the risk of bleeding [12].

Altogether, these limitations and complications of VKA therapy may dissuade physicians from prescribing VKAs to the elderly [8,13]. Low Molecular Weight Heparins (LMWHs) provide a more predictable anticoagulant effect but require parenteral administration, limiting their long-term use [8].
Over the recent years, non-VKA-acting Oral Anticoagulants (NOACs) have become available for the prevention and treatment of VTE and for the prevention of atrial fibrillation related stroke. The efficacy and safety of the thrombin inhibitor dabigatran etexilate and the factor Xa inhibitors rivaroxaban, apixaban and edoxaban for the treatment and secondary prevention of VTE have been demonstrated in large phase III programs [1,3,14-18].

NOACs offer several advantages over VKAs. First, due to their more predictable pharmacodynamics and limited drug interactions, NOACs do not require routine coagulation monitoring. Secondly, they exhibit a faster on- and off-set compared to VKAs, which may offer a benefit when bleeding complications occur, and which facilitates the periprocedural management of anticoagulation.

In elderly patients, however, these characteristics of NOACs may be challenging. Although the use of a fixed dose regimen is convenient both for patients and physicians, there could be a risk for increased drug exposure in patients with reduced drug clearance [8]. This issue is of particular importance for the direct thrombin inhibitor dabigatran etexilate, which is mainly eliminated via the kidney.

Furthermore, the shorter half-life of NOACs poses a potential risk when doses are skipped due to non-compliance or forgetfulness. It is uncertain if this variability may unfavorably alter the balance between risk and benefits of real-life treatment in the elderly patients [19].

The purpose of this study was to review the efficacy and safety of NOACs in the elderly and in renal impaired patients.

Methods

Search strategy

We limited this review to NOACs that are either approved for the treatment of VTE or under consideration for such approval by the European Medicine Agency. All phase III randomized controlled trials comparing the selected NOACs with VKA therapy for the initial treatment of VTE were included. From these trials, all available analyses for age and renal function subgroups were obtained from the original publications, from their online supplements, or abstract presentations at major conferences. We compared patients ≥75 years with patients <75 years, and patients with impaired renal function with patients with preserved renal function, using a cutoff of a creatinine clearance (CrCl) of 50 ml/min (Cockcroft-Gault formula), except in the RECOVER subgroups were the reported cutoff for age was >75 vs. ≤75 and for renal function ≥50 ml/min vs. <50 ml/min.

For each trial, risk ratios (RRs) and 95% confidence intervals (95% CIs) of NOACs vs. VKA therapy were obtained or calculated if not reported. For subgroups, P interaction was calculated [20]. We compared recurrence rates across trials and in a pooled analysis for patients over 75 years old vs. younger patients, and for patients with a reduced vs. normal renal function for NOAC treatment and VKA treatment arms separately. Furthermore, we performed a meta-analysis for the relative efficacy as well as safety of NOACs vs. VKA in patients over 75 years and in patients with a reduced renal clearance. RRs and corresponding 95% CIs were calculated for the individual trials and pooled according to the Mantel-Haenszel method, using a random effect model (Review Manager 5.2).

Study outcomes and definitions

In all selected trials, efficacy outcomes were recurrent VTE or death related to VTE. The primary safety outcome was major bleeding in all trials besides the HOKUSAI-VTE trial, where the combination of major and clinically relevant non-major (CRNM) bleeding was the primary safety outcome. The definition of major bleeding was similar in all included studies and conform the International Society on Thrombosis and Haemostasis guidelines [21].

Results

Four NOACs were either recently approved (rivaroxaban, dabigatran) or are in the regulatory approval process (apixaban, edoxaban) for treatment of VTE. The study characteristics are summarized in Table 1. The different subgroup analyses for efficacy and safety outcomes in the elderly and renal impaired are summarized in Figures 1, 2, 3, and 4.

Dabigatran

In RE-COVER I and II, only 10.4% (N = 529) were aged ≥75 years and only 5.2% (N = 267) had a CrCl ≤50 ml/min [17,18]. There was no significant difference in efficacy of heparin followed by dabigatran 150 mg BID vs. heparin/VKA in patients aged over 75, however, only 8 events occurred in this age group, limiting statistical power (Figure 1). In the subgroup of patients with reduced renal function, the rate of recurrence was lower in patients randomized to dabigatran compared to VKA-treated patients, however, this was non-significant due to the large confidence interval (RR 0.11 95% CI 0.01-1.88) (Figure 2).

Both elderly patients and patients with reduced renal clearance had a markedly higher bleeding risk regardless of their treatment with dabigatran 150 mg BID or warfarin Figures 3 and 4). Although dabigatran was associated with a reduction in major bleeding in the overall trial results [17,18], this reduction was no longer seen in the subgroups of elderly patients and patients with reduced renal clearance, where the rate of major bleeding
was similar in patients treated with dabigatran and warfarin with a RR of 0.91 (95% CI 0.37-2.19) for age >75 and 1.29 (95% CI 0.43-3.89) for clearance <50 ml/min. (Figures 3 and 4) [24,25]. Importantly, the reported subgroup analyses excluded the heparin lead-in phase, which restricts the evaluation of the safety of the overall strategy.

**Rivaroxaban**

Together, both EINSTEIN trials included 1283 patients (18%) aged ≥75 [14,15], and 664 patients (8%) with renal impairment. The risk for recurrence increased from 2.1% in younger patients to 3.7% in patients over 75 years old (P = 0.02) in patients randomized to warfarin (Figure 1). In contrast, there was no age-dependent increase in recurrence in the rivaroxaban-arm: 2.3% in aged ≥75 vs. 2.0% in aged <75 years (p = 0.07). In patients with reduced renal function, the rate of recurrence was increased by over 50% in both rivaroxaban- and VKA-treated patients. There was no significant effect of renal function on the relative efficacy of rivaroxaban compared to VKA (Figure 2).

In the EINSTEIN trials, treatment with rivaroxaban was associated with a 45% overall reduction in major bleeding [16]. When analyzed by subgroup, the reduction in major bleeding was more prominent in the age group ≥75 years (RR 0.27, 95% CI 0.13-0.59; p = 0.001) (Figure 3) [16,19]. In warfarin-treated patients, major bleeding rates were 3.5 times higher in patients over 75 years old (4.5 vs. 1.3%, p = 0.02). In contrast, age above 75 did not significantly increase the bleeding rates in rivaroxaban-treated patients (1.2 vs. 0.9%, p = 0.62) (Figure 5). The reduction in major bleeding with rivaroxaban vs. warfarin was consistent in patients with conserved and patients with impaired renal function (RR 0.63 (95% CI 0.42-0.94) and 0.22 (95% CI 0.06-0.78), respectively) (Figure 4).

**Apixaban**

In AMPLIFY, 14% (N = 768) of the patients were aged 75 years or more and 6.2% (N = 327) had a reduced renal function [1]. Compared to those aged <75, there was a trend towards a better efficacy of apixaban compared with warfarin in older patients (Figure 1). In patients

| Study       | NOAC | NOAC% (n/N) | Warfarin% (n/N) | Risk Ratio (95% CI) | P-value | P-interaction |
|-------------|------|-------------|-----------------|---------------------|---------|---------------|
| RE-COVER I & II | Dabigatran | Overall  2.4 (60/2553) | 2.2 (55/2554) | 1.09 (0.76-1.56) | 0.64 | 0.70 |
|             |       | ≥75 years  2.1 (57/2553) | 2.2 (50/2554) | 1.13 (0.78-1.64) | 0.53 |     |
|             |       | >75 years  1.2 (18/2553) | 1.8 (25/2554) | 0.65 (0.17-2.45) | 0.56 |     |
| EINSTEIN DVT & PE | Rivaroxaban | Overall  1.8 (84/4595) | 2.3 (95/4331) | 0.79 (0.68-1.28) | 0.48 | 0.47 |
|             |       | ≥75 years  2.1 (71/3494) | 2.1 (72/3504) | 0.98 (0.71-1.37) | 0.95 |     |
|             |       | >75 years  2.3 (158/5656) | 3.7 (238/627) | 0.62 (0.33-1.17) | 0.15 |     |
| AMPLIFY | Apixaban | Overall  2.3 (39/2699) | 2.7 (71/2638) | 0.84 (0.69-1.08) | 0.31 | 0.41 |
|             |       | ≥75 years  2.3 (52/2220) | 2.5 (56/2279) | 0.92 (0.63-1.32) | 0.65 |     |
|             |       | >75 years  1.8 (73/389) | 3.6 (13/386) | 0.50 (0.21-1.20) | 0.13 |     |
| HOKUSAI* | Edoxaban | Overall  3.2 (130/4118) | 3.5 (146/4122) | 0.89 (0.71-1.22) | 0.33 | 0.18 |
|             |       | ≥75 years  3.3 (116/3558) | 3.1 (119/3578) | 0.98 (0.76-1.32) | 0.87 |     |
|             |       | >75 years  2.5 (14/560) | 5.0 (27/544) | 0.50 (0.27-0.94) | 0.03 |     |
treated with warfarin, there was a 44% increase in event rates in older patients compared to younger patients. In contrast, in the apixaban-arm, event rates in older patients were not elevated compared to younger patients (Figure 1). Subgroup analysis for renal function showed similar efficacy in both renal function classes (Figure 2). However, either type of anticoagulant treatment was less effective in renally impaired patients, as shown by a 70% increase in recurrence rates compared to patients with normal renal function, regardless of the treatment (Figure 2).

With regard to the primary safety outcome, apixaban significantly reduced major bleeding with 70% compared to warfarin in the overall analysis, and this reduction remained significant both in younger and in elderly patients (Figure 3). The RR in patients with normal renal

| Study          | NOAC          | NOAC% (n/N) | Warfarin% (n/N) | Risk Ratio (95% CI) | P-value | P-interaction |
|----------------|---------------|-------------|-----------------|--------------------|---------|---------------|
| RE-COVER I & II | Dabigatran    | Overall: 2.4 (40/253) | 2.2 (55/254) | 1.09 (0.76-1.56) | 0.64    | 0.07          |
|                |               | CrCl ≥50: 2.5 (60/2424) | 2.1 (50/2395) | 1.18 (0.62-1.71) | 0.36    |               |
|                |               | CrCl <50: 0.0 (0/129) | 3.6 (5/132)  | 0.10 (0.01-1.74) | 0.11    |               |
| EINSTEIN DVT & PE | Rivaroxaban  | Overall: 1.8 (86/4580) | 2.3 (95/4131) | 0.90 (0.68-1.20) | 0.48    | 0.54          |
|                |               | CrCl ≥50: 1.9 (42/2373) | 2.2 (42/2379) | 0.89 (0.65-1.12) | 0.46    |               |
|                |               | CrCl <50: 3.3 (11/332)  | 3.4 (13/1032) | 0.96 (0.63-2.21) | 0.94    |               |
| AMPLIFY        | Apixaban      | Overall: 2.3 (59/2649) | 2.7 (71/2635) | 0.84 (0.60-1.18) | 0.31    | 0.97          |
|                |               | CrCl ≥50: 2.4 (52/2207) | 2.4 (54/2249) | 0.98 (0.67-1.43) | 0.92    |               |
|                |               | CrCl <50: 4.1 (7/158)  | 4.4 (7/158)  | 0.93 (0.34-2.50) | 0.89    |               |
| HOKUSAI*       | Edoxaban      | Overall: 3.2 (130/4118) | 3.5 (146/4122) | 0.89 (0.71-1.12) | 0.33    | 0.33          |
|                |               | CrCl ≥50: 3.2 (122/3850) | 3.4 (130/3849) | 0.93 (0.74-1.20) | 0.60    |               |
|                |               | CrCl <50: 3.0 (8/268)  | 3.9 (16/273)  | 0.31 (0.22-1.14) | 0.11    |               |

CrCl: Creatinine clearance (ml/min); *Numbers given for the overall study period

Figure 2 Efficacy according to renal function.

| Study          | NOAC          | NOAC% (n/N) | Warfarin% (n/N) | Risk Ratio (95% CI) | P-value | P-interaction |
|----------------|---------------|-------------|-----------------|--------------------|---------|---------------|
| RE-COVER I & II | Dabigatran    | Overall: 1.0 (24/2456) | 1.6 (40/2462) | 0.60 (0.36-0.99) | 0.047   | 0.64          |
|                |               | ≤75 years: 0.7 (16/2225) | 1.4 (30/2200) | 0.53 (0.29-0.96) | 0.038   |               |
|                |               | >75 years: 3.5 (8/231)  | 3.8 (10/262)  | 0.91 (0.37-2.19) | 0.83    |               |
| EINSTEIN DVT & PE | Rivaroxaban  | Overall: 1.0 (40/4130) | 1.7 (72/4136) | 0.55 (0.38-0.83) | 0.003   | 0.04          |
|                |               | ≤75 years: 0.9 (32/3475) | 1.3 (44/3492) | 0.73 (0.47-1.15) | 0.17    |               |
|                |               | >75 years: 1.2 (8/655)  | 4.5 (24/223)  | 0.27 (0.13-0.59) | <0.001  |               |
| AMPLIFY        | Apixaban      | Overall: 0.5 (15/2676) | 1.8 (49/2689) | 0.31 (0.17-0.54) | 0.001   | 0.40          |
|                |               | ≤75 years: 0.5 (11/2278) | 1.4 (33/2319) | 0.34 (0.17-0.67) | 0.002   |               |
|                |               | >75 years: 1.0 (4/398)  | 4.3 (16/370)  | 0.23 (0.08-0.65) | 0.009   |               |
| HOKUSAI        | Edoxaban      | Overall: 0.8 (15/2676) | 1.8 (49/2689) | 0.31 (0.17-0.54) | 0.001   | 0.40          |
|                |               | ≤75 years: 0.8 (11/2278) | 1.4 (33/2319) | 0.34 (0.17-0.67) | 0.002   |               |
|                |               | >75 years: 1.0 (4/398)  | 4.3 (16/370)  | 0.23 (0.08-0.65) | 0.009   |               |

Data for major bleeding in the HOKUSAI trial and major + CRNM bleeding in the AMPLIFY trial were not reported in the original studies

Figure 3 Safety according to age.
function and reduced renal function was similar (P interaction 0.36) but the safety benefit was no longer significant in patients with impaired renal function (P-value 0.22) (Figure 4) [1].

**Edoxaban**

In the HOKUSAI trial 12% (N = 1004) of included patients were aged 75 years or older, and 6.6% (N = 541) had a CrCl ≤50 ml/min [3]. Subgroup analysis showed a statistically significant 50% reduction of recurrent VTE in edoxaban-treated patients compared to VKA-treated patients for those patients aged 75 years or older (RR 0.50; 95% CI 0.26 to 0.95, p = 0.03) whereas there was no apparent difference in younger patients (RR 0.98 (95% CI 0.74-1.26; p = 0.87) (Figure 1). Edoxaban was equivalent to warfarin in terms of bleeding outcomes, irrespective of the age subgroups (Figure 3). The HOKUSAI trial was unique for the fact that a planned dose reduction (30 mg instead of 60 mg) was foreseen for patients with CrCl 30–50 ml/min or a body weight less than 60 kg. In patients with reduced renal function, there was a non-significant trend towards greater efficacy of edoxaban vs. warfarin (RR of 0.51; 95% CI 0.22-1.17) compared to patients with a normal renal function (RR of 0.93; 95% CI 0.74-1.20) (Figure 2). Bleeding risk in this subgroup was similar with edoxaban and warfarin (Figure 4).

**Pooled data and meta-analysis**

In patients treated with warfarin, the rate of VTE recurrence was higher in patients aged over 75, with a pooled risk ratio of 1.47 (95% CI 1.13-1.90) compared to warfarin-treated patients <75 years. In contrast, patients ≥75 treated with NOACs did not have an increased recurrence compared to younger patients (RR 0.83, 95% CI 0.59-1.15) (Figure 6A, B). Thus, in a meta-analysis of all patients over 75, NOACs were more effective compared to warfarin (risk ratio for recurrence 0.55 (95% CI 0.38-0.82) (Figure 7A).

Renal impairment was associated with an increased risk of recurrence in the warfarin-arms of all trials. Although not significant in most individual trials, pooled data show a significant 71% risk increase in patients with reduced renal clearance. A similar increase in recurrence was noted in patients with reduced renal function treated with apixaban or rivaroxaban, but not in patients treated with dabigatran or edoxaban. A pooled analysis showed no significant difference in relative efficacy between NOACs and warfarin in patients with renal dysfunction (relative risk ratio 0.71, 95% CI 0.41-1.21) (Figure 7B).

Because the rates of major bleedings in the subgroups of interest were not reported for the HOKUSAI trial, the edoxaban-study was not included in the safety meta-analyses. Overall, NOACs were associated with a reduced risk of major bleeding in elderly patients compared to

---

### Table: Safety according to renal function

| Study     | NOAC  | NOACs (%) (n/N) | Warfarin (%) (n/N) | Risk Ratio (95% CI) | P-value | P-interaction |
|-----------|-------|-----------------|--------------------|---------------------|---------|---------------|
| Major bleeding |       |                 |                    |                     |         |               |
| RECOVER I & II | Dalteparin | CrCl <50 | 0.8 (18/2319) | 1.5 (35/2319) | 0.52 (0.29-0.90) | 0.022 | 0.67 |
|              | CrCl ≥50 | 1.7 (6/106)    | 4.4 (1/114)       | 1.29 (0.43-3.89)   | 0.67    |               |
| EINSTEIN DVT & PE | Rivaroxaban | CrCl <50 | 1.0 (37/3754) | 1.6 (56/3754) | 0.63 (0.42-0.94) | 0.036 | 0.09 |
|              | CrCl ≥50 | 0.9 (3/329)    | 4.1 (13/329)     | 0.22 (0.06-0.73)   | 0.019   |               |
| AMPLIFY | Apixaban | CrCl <50 | 0.5 (15/2876) | 1.8 (49/2876) | 0.31 (0.17-0.55) | 0.001 | 0.56 |
|              | CrCl ≥50 | 2.4 (5/2179)   | 5.5 (9/2179)     | 0.51 (0.18-1.44)   | 0.22    |               |

**Figure 4 Safety according to renal function.**

Data for major bleeding in the HOKUSAI trial and major CRNM bleeding in the AMPLIFY trial were not reported in the original studies.
warfarin (relative risk ratio 0.39, 95% CI 0.17-0.90) (Figure 7C). Elderly patients treated with apixaban or rivaroxaban appeared to have a greater safety benefit compared to VKAs than those treated with dabigatran (relative risk ratios 0.23, 95% CI 0.08-0.69 and 0.27, 95% CI 0.13-0.59 for apixaban and rivaroxaban respectively vs. 0.91 95% CI 0.36-2.26 for dabigatran). In the subgroup of patients with reduced renal function, the pooled analysis shows a trend towards a reduction in bleeding risk (relative risk ratio 0.54, 95% CI 0.21-1.42) (Figure 7D).
We reviewed the available data regarding efficacy and safety in the phase III trials of NOACs for the acute treatment of VTE in the elderly and renally impaired. The pooled data presented here give information on two clinically relevant questions: first, what is the impact of age or reduced renal clearance on the risk of recurrence or bleeding, and secondly, how do NOACs compare to VKA in these subgroups.

In the subgroup of elderly patients or patients with reduced clearance, treatment with VKA is both less effective (50 to 70% increase in recurrence) and less safe (about 3-fold increased risk of bleeding). This is in line with finding from previous studies, reporting an increased risk for both bleeding and (recurrent) thrombosis in these frail patients when treated with conventional anticoagulation [4,6,26].

This could be the result of a reduced quality of VKA management in frailer patients, or an increased susceptibility for thrombotic or bleeding complications. To our knowledge, time into therapeutic range (TTR) as a function of age or renal function subgroups has not been reported for these trials.

In contrast with VKA, NOACs were not associated with a significant increase in recurrence in subgroups of frail patients. In the meta-analyses, NOACs were more effective than warfarin in the subgroup of elderly patients, and there was a trend towards better efficacy in patients with reduced renal function. There are two possible explanations for this
### A) VTE recurrence in the subgroup age ≥75 years

| Study or Subgroup | NOAC Events | NOAC Total | Warfarin Events | Warfarin Total | Weight | Risk Ratio M–H, Random, 95% CI | Risk Ratio M–H, Random, 95% CI |
|-------------------|-------------|------------|----------------|----------------|--------|--------------------------------|--------------------------------|
| AMPLIFY           | 7           | 389        | 13             | 360            | 18.3%  | 0.50 [0.20, 1.24]              |                                |
| EINSTEIN DVT & PE | 15          | 656        | 23             | 627            | 36.7%  | 0.62 [0.33, 1.18]              |                                |
| HOKUSAI           | 14          | 560        | 27             | 544            | 37.5%  | 0.50 [0.27, 0.95]              |                                |
| RECOVER I & II    | 3           | 253        | 5              | 276            | 7.5%   | 0.65 [0.16, 2.71]              |                                |
| **Total (95% CI)**| **1858**    | **1807**   | **100.0%**     |                |        | **0.55 [0.38, 0.82]**          |                                |

Total events: 39 | 68

Heterogeneity: Tau² = 0.00; Chi² = 0.32, df = 3 (P = 0.96); I² = 0%
Test for overall effect: Z = 2.98 (P = 0.003) 

| Favo [NOAC] | Favo [Warfarin] |
|-------------|-----------------|
| 0.1 | 0.2 | 0.5 | 1 | 2 | 5 | 10 |

### B) VTE recurrence in the subgroup CrCl ≤50 ml/min

| Study or Subgroup | NOAC Events | NOAC Total | Warfarin Events | Warfarin Total | Weight | Risk Ratio M–H, Random, 95% CI | Risk Ratio M–H, Random, 95% CI |
|-------------------|-------------|------------|----------------|----------------|--------|--------------------------------|--------------------------------|
| AMPLIFY           | 7           | 169        | 7              | 158            | 24.7%  | 0.93 [0.34, 2.61]              |                                |
| EINSTEIN DVT & PE | 11          | 332        | 11             | 322            | 36.3%  | 0.97 [0.43, 2.11]              |                                |
| HOKUSAI           | 8           | 268        | 16             | 273            | 35.5%  | 0.51 [0.22, 1.17]              |                                |
| RECOVER I & II    | 0           | 129        | 5              | 138            | 3.4%   | 0.10 [0.01, 1.74]              |                                |
| **Total (95% CI)**| **898**     | **891**    | **100.0%**     |                |        | **0.71 [0.41, 1.21]**          |                                |

Total events: 26 | 39

Heterogeneity: Tau² = 0.03; Chi² = 3.35, df = 3 (P = 0.34); I² = 10%
Test for overall effect: Z = 1.26 (P = 0.21)

| Favo [NOAC] | Favo [Warfarin] |
|-------------|-----------------|
| 0.1 | 0.2 | 0.5 | 1 | 2 | 5 | 10 |

### C) Major bleeding in the subgroup age ≥75 years

| Study or Subgroup | NOAC Events | NOAC Total | VKA Events | VKA Total | Weight | Risk Ratio M–H, Random, 95% CI | Risk Ratio M–H, Random, 95% CI |
|-------------------|-------------|------------|------------|-----------|--------|--------------------------------|--------------------------------|
| AMPLIFY           | 4           | 398        | 16         | 370       | 28.8%  | 0.23 [0.08, 0.69]              |                                |
| EINSTEIN DVT & PE | 8           | 655        | 28         | 624       | 37.6%  | 0.27 [0.13, 0.59]              |                                |
| HOKUSAI           | 0           | 0          | 0          | 0         | Not estimable |                                |
| RECOVER I & II    | 8           | 231        | 10         | 262       | 33.6%  | 0.91 [0.36, 2.26]              |                                |
| **Total (95% CI)**| **1284**    | **1256**   | **100.0%** |           |        | **0.39 [0.17, 0.90]**          |                                |

Total events: 20 | 54

Heterogeneity: Tau² = 0.33; Chi² = 5.02, df = 2 (P = 0.08); I² = 60%
Test for overall effect: Z = 2.20 (P = 0.03)

| Favo [NOAC] | Favo [VKA] |
|-------------|------------|
| 0.1 | 0.2 | 0.5 | 1 | 2 | 5 | 10 |

### D) Major bleeding in the subgroup CrCl ≤50 ml/min

| Study or Subgroup | NOAC Events | NOAC Total | VKA Events | VKA Total | Weight | Risk Ratio M–H, Random, 95% CI | Risk Ratio M–H, Random, 95% CI |
|-------------------|-------------|------------|------------|-----------|--------|--------------------------------|--------------------------------|
| AMPLIFY           | 5           | 175        | 9          | 163       | 35.8%  | 0.52 [0.18, 1.51]              |                                |
| EINSTEIN DVT & PE | 3           | 329        | 13         | 320       | 30.9%  | 0.22 [0.06, 0.78]              |                                |
| HOKUSAI           | 0           | 0          | 0          | 0         | Not estimable |                                |
| RECOVER I & II    | 6           | 106        | 5          | 114       | 33.3%  | 1.29 [0.41, 4.10]              |                                |
| **Total (95% CI)**| **610**     | **597**    | **100.0%** |           |        | **0.54 [0.21, 1.42]**          |                                |

Total events: 14 | 27

Heterogeneity: Tau² = 0.37; Chi² = 4.13, df = 2 (P = 0.13); I² = 52%
Test for overall effect: Z = 1.25 (P = 0.21)

| Favo [NOAC] | Favo [VKA] |
|-------------|------------|
| 0.1 | 0.2 | 0.5 | 1 | 2 | 5 | 10 |

Figure 7 Meta-analyses.
improved efficacy, both of which likely contribute to the observed effect.

First, the more predictable pharmacokinetics of NOACs may offer better protection against recurrence than warfarin in subgroups with more challenging warfarin management [12]. If the improved efficacy of NOACs vs. warfarin in these subgroups is due to more stable pharmacokinetics, NOACs could also be expected to be associated with a lower risk of bleeding in these subgroups. This was true for apixaban and rivaroxaban, but not for dabigatran.

Secondly, accumulation of NOACs due to reduced renal clearance may lead to a higher intensity of anticoagulation, which may in turn overcome an increased prothrombotic state in these subgroups. This is supported by the finding that dabigatran, which is approximately 80% renally cleared, was associated with the strongest reduction in recurrence in patients with renal insufficiency.

Altogether, the data from the NOAC trials in patients with VTE suggest that NOACs offer better overall safety and efficacy profiles in elderly patients, and comparable safety and efficacy profiles in patients with moderate renal insufficiency. Although the overall findings are reassuring with regards to the use of NOACs in these subgroups of frail patients, some points should be highlighted.

First, interpretations regarding subgroup analyses should always be made with caution, since those trials are insufficiently powered for subgroups. In a meta-analysis comparing NOACs vs. warfarin in atrial fibrillation [27], which had considerably more statistical power due to the larger trial size and the higher mean age of included patients, NOACs were associated with a trend towards better efficacy and comparable safety in the elderly and renally impaired. Despite the different patient population, it is reassuring that the global results are in line with our findings. Second, combined results for elderly patients with renal dysfunction are not reported, hence we cannot provide data on this specific group. Third, it should be noted that, although NOACs performed as good as VKA in these patients, the absolute rates for both recurrence and (major) bleeding were higher in patients with moderately reduced renal function (up to 7-fold increase). This stresses the importance of renal function as a risk factor, and posed a dilemma for the clinician as a dose-reduction in patients with a reduced renal function might not be the best strategy to improve the overall risk-benefit ratio. Interesting in this regard are the findings from the HOKUSAI trial. Although the HOKUSAI study suggests that the use of a prespecified dose reduction ensured a similar safety as well as a conserved efficacy in patients with reduced renal function compared to normal renal function, these results were not different from the other trials, where no such dose reduction was prespecified. Lastly, all trials used different types and duration of initial therapies, and not all bleeding outcomes in relation to the subgroups of interests have yet been reported, potentially confounding the safety profile in our meta-analysis.

Perhaps the most challenging question is to which extent these results from clinical trials apply to real-world patients. In general, clinical trial patients represent a selected population with minimal comorbidities and concomitant medication use and optimal compliance, all of which are particular challenges in elderly patients. Therefore, the discrepancy between clinical trial populations and the ‘real world’ patients is likely to be even larger in older age groups. Furthermore, the trials included very few patients over 80 or 90 years old, and excluded patients with severe renal insufficiency or with a high risk of bleeding. Thus, the frailest patients may not be adequately represented. Nonetheless, the same phenomenon applies to VKA treatment. The quality of warfarin management, reflected in the TTR, ranged from 57% in EINSTEIN DVT [14] to 64% in HOKUSAI [3] compared to about only 40% in real life registries and daily clinical practice [3]. Although TTR was not reported as a function of age subgroups, the quality of VKA strengthens the external validity of these studies [28].

These limitations highlight the importance of post-marketing registries in real-world patients [19]. In a recent Food and Drug Administration (FDA) report of bleeding complications of dabigatran vs. warfarin in atrial fibrillation patients derived from insurance-claim and administrative data, there was no evidence that real-world rates of bleeding with dabigatran were higher than with warfarin [29]. This report provides some, albeit indirect, reassurance about the external validity of the trial results, but more real-world data is needed in the appropriate patient group.

The subgroup data presented here have important clinical implications. The available evidence demonstrates that NOACs are at least as safe as VKA treatment, and may offer a better efficacy in elderly patients or patients with moderate renal dysfunction who otherwise match the in- and exclusion criteria of the clinical trials. In the absence of head-to-head comparisons between NOACs, it is not possible to directly compare different NOACs. Nevertheless, the relative efficacy of NOACs in the elderly and in patients with low renal clearance was very similar.

In conclusion, data from the published trials suggest that NOACs may be more effective than warfarin in the treatment of acute VTE in the elderly population, and as effective as warfarin in patients with moderate renal dysfunction. Furthermore, there was no increased risk of bleeding with NOACs compared to warfarin in these subgroups. However, these results are based on a relatively small numbers of events, highlighting the need for appropriately designed and powered studies in these subgroups. Furthermore, the question remains to which extent these results can be translated to a less selected population. Future data from observational studies and registries are needed to clarify the benefit/risks profile of NOACs in the real world.
Competing interests
Peter Verhamme has received research grants or served as a consultant or speaker for: Bayer HealthCare; LegoPharma; Boehringer Ingelheim; Daiichi Sankyo; Pfizer; Sanofi-Aventis; ThromboGenics.

The authors declare that they have no competing interests.

Authors’ contributions
VG performed literature search, VG and TV performed statistical analysis, all authors contributed to writing of the manuscript. All authors read and approved the final manuscript.

Author details
1Division of Internal Medicine, University Hospitals Leuven, Herestraat 49, Leuven B-3000, Belgium. 2Vascular Medicine and Haemostasis, Division of Cardiovascular Diseases, University Hospitals Leuven, Herestraat 49, Leuven B-3000, Belgium. 3Center for Molecular and Vascular Biology (CMVB), Department of Cardiovascular Sciences, University of Leuven, Herestraat 49, Leuven B3000, Belgium.

Received: 10 April 2014 Accepted: 16 September 2014
Published: 13 October 2014

References
1. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masukiewicz U, Pak R, Thompson J, Raskob GE, Weitcz JK, AMPLIFY investigators: Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013, 369:99–808.
2. Goldhaber SZ. Venous disease. In: Cardiovascular Medicine, London Limited. 3rd edition. Edited by Willerson JT, Cohn JN, Wellein HJ, Holmers DR. 2007:1705–1716.
3. Hokusa VTE Investigators, Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho LR, Segers A, Shi M, Verhamme P, Wells P. Edoxaban versus warfarin for the treatment of venous thromboembolism. N Engl J Med 2013, 369:1405–1415.
4. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forciea A, Dalen JE: A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT study. Arch Intern Med 1991, 151:933–938.
5. Stein PD, Hull RD, Kavall G, Ghali WA, Alichak AK, Olsen RE: Venous thromboembolism according to age: the impact of an aging population. Arch Intern Med 2004, 164:2260–2265.
6. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O’Fallon WM, Melton LJ III: Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000, 160:641–648.
7. Laporte S, Mismetti P, Decousus H, Ursenbold F, Otero R, Lobo JL, Monreal M, Investigators R: Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry, Circulation 2008, 117:1711–1716.
8. Bausersach R: Use of anticoagulants in elderly patients. Thromb Res 2012, 129:107–115.
9. Nieto JA, Solano R, Ruiz-Ribo MD, Ruiz-Gimenez N, Prandoni P, Kearon C, Monreal M, Rete I: Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2010, 8:1216–1222.
10. Prandoni P, Trujillo-Santos J, Sanchez-Cantalejo E, Dalla Valle F, Piovella C, Pesavento R, Nieto Rodriguez JA, Monreal M, Group R. Major bleeding as a predictor of mortality in patients with venous thromboembolism: findings from the RIETE Registry. J Thromb Haemost 2010, 8:2575–2577.
11. Trujillo-Santos J, Herrera S, Page MA, Soto MJ, Raventos A, Sanchez R, Monreal M, Investigators R: Predicting adverse outcomes in outpatients with acute deep vein thrombosis: findings from the RIETE registry. J Vasc Surg 2008, 48:799–795.
12. Sigert V, Pautas E, Gouin-Thibault I: Vitamin K antagonist use in the elderly: special considerations. Future Cardiol 2007, 3:321–330.
13. White RH, McBurnie MA, Manolio T, Furberg CD, Gardin JM, Kttner SJ, Bovill E, Knepper L: Oral anticoagulation in patients with atrial fibrillation: adherence with guidelines in an elderly cohort. Am J Med 1999, 106:165–171.
14. Investigators E, Bausersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus A, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S: Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363:2499–2510.
15. Investigators EP, Buller HR, Prins MH, Lensing AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli C, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A: Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012, 366:1287–1297.
16. Prins MH, Lensing AW, Bausersachs R, Van Bellen B, Bounameaux H, Bright TA, Cohen AT, Davidson BL, Decousus H, Raskob GE, Berkowitz SD, Wells PS, EINSTEIN Investigators: Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013, 11:21.
17. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Mauff P, Peter N, Kearon C, RE-SONATE Trial Investigators. Treatment of acute venous thromboembolus with dabigatran or warfarin and placebo in the anatomic circulation. Circulation 2014, 129:764–772.
18. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ, Group R-C: Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361:2342–2352.
19. Barco S, Cheung WW, Eikelboom JW, Coppins M: New oral anticoagulants in elderly patients. Best Pract Res Clin Haematol 2013, 26:215–224.
20. Altman DG, Bland JM: Interaction revisited: the difference between two estimates. Br Med J 2003, 326:219.
21. Schulman S, Beyth RJ, Kearon C, Levine MN, American College of Chest: Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:2575–2585.
22. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kramme AM, Friedman J, Mismetti P, Goldhaber SZ, RE-MEDY Trial Investigators, RE-SONATE Trial Investigators: Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013, 368:709–718.
23. Van der Hulle T, Koelm J, Den Ester PL, Dekkers OM, Klok FA, Husman MW: Effectiveness and safety of novel oral anticoagulants compared with vitamin K-antagonists in the treatment of acute symptomatic venous thromboembolism- a systematic review and meta-analysis. J Thromb Haemost 2014, 12:320–328.
24. Schulman S, Eriksson H, Goldhaber SZ, Kakkar A, Kearon C, Schellong SM, Feuring M, Peter N, Friedman J: Influence of renal function on the efficacy and safety of dabigatran-versus warfarin for the treatment of acute venous thromboembolism in pooled analysis from RE-COVER and RE-COVER II. Blood 2013, 122:2375.
25. Schulman S, Eriksson H, Goldhaber SZ, Kakkar A, Kearon C, Schellong SM, Kreuzer J, Peter N, Friedman J: Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood 2013, 122:2375.
26. Poli D, Antonucci E, Griffone E, Abbate R, Gensini GF, Prisco D: Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol 2009, 54:999–1002.
27. Ruf CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Cramm AJ, Weitz II, Lewis BS, Parikh Naik P, Yarnassita T, Antman EM: Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2013, 383(9921):955–962.
28. Verhamme P, Bounameaux H: Direct oral anticoagulants for acute venous thromboembolism: closing the circle? Circulation 2014, 129:725–727.
29. Southworth MR, Reichman ME, Unger EF, Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013, 368:1272–1274.

Cite this article as: Geldhof et al.: Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants. Thrombosis Research 2014 12:21.

doi:10.1186/1477-9560-12-21